Sex: U
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vomiting
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch); Moderate injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Moderate fatigue with some interference with activity; Moderate muscle pain with some interference with activity; Joint pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness) and VACCINATION SITE SWELLING (Mild injection site swelling) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: 100.4 to 101.2 °F.         Concomitant medications were not reported. The event experienced anytime during the 2 days after your COVID-19 vaccination, which occurred on Monday, Dec 18, 2023 and Tuesday, Dec 19, 2023. Severity was reported as Moderate for injection site pain interfering with activity and Mild for injection site tenderness (tender to touch) Subject ID was reported as  57819-34126 Agency Subject ID was reported as 5472791 No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2024-756041 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756041:Same reporter